AU2017319728B2 - Depot systems comprising glatiramer acetate - Google Patents

Depot systems comprising glatiramer acetate Download PDF

Info

Publication number
AU2017319728B2
AU2017319728B2 AU2017319728A AU2017319728A AU2017319728B2 AU 2017319728 B2 AU2017319728 B2 AU 2017319728B2 AU 2017319728 A AU2017319728 A AU 2017319728A AU 2017319728 A AU2017319728 A AU 2017319728A AU 2017319728 B2 AU2017319728 B2 AU 2017319728B2
Authority
AU
Australia
Prior art keywords
patient
depot formulation
depot
glatiramer
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017319728A
Other languages
English (en)
Other versions
AU2017319728A1 (en
Inventor
Nadav BLEICH KIMELMAN
Uri DANON
Ehud Marom
Shai Rubnov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of AU2017319728A1 publication Critical patent/AU2017319728A1/en
Application granted granted Critical
Publication of AU2017319728B2 publication Critical patent/AU2017319728B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Vapour Deposition (AREA)
  • Epoxy Compounds (AREA)
AU2017319728A 2016-08-31 2017-08-09 Depot systems comprising glatiramer acetate Active AU2017319728B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381598P 2016-08-31 2016-08-31
US62/381,598 2016-08-31
PCT/IL2017/050882 WO2018042415A1 (en) 2016-08-31 2017-08-09 Depot systems comprising glatiramer acetate

Publications (2)

Publication Number Publication Date
AU2017319728A1 AU2017319728A1 (en) 2019-02-07
AU2017319728B2 true AU2017319728B2 (en) 2024-09-05

Family

ID=61300274

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017319728A Active AU2017319728B2 (en) 2016-08-31 2017-08-09 Depot systems comprising glatiramer acetate

Country Status (21)

Country Link
US (1) US12370233B2 (cg-RX-API-DMAC7.html)
EP (2) EP3506921B1 (cg-RX-API-DMAC7.html)
JP (1) JP7193448B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982712A (cg-RX-API-DMAC7.html)
AU (1) AU2017319728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035147A1 (cg-RX-API-DMAC7.html)
DK (1) DK3506921T3 (cg-RX-API-DMAC7.html)
ES (2) ES2952044T3 (cg-RX-API-DMAC7.html)
FI (1) FI3506921T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20230738T1 (cg-RX-API-DMAC7.html)
HU (2) HUE062393T2 (cg-RX-API-DMAC7.html)
IL (2) IL301455B2 (cg-RX-API-DMAC7.html)
LT (1) LT3506921T (cg-RX-API-DMAC7.html)
MX (1) MX2019002284A (cg-RX-API-DMAC7.html)
PL (2) PL3506921T3 (cg-RX-API-DMAC7.html)
PT (1) PT3506921T (cg-RX-API-DMAC7.html)
RS (2) RS66690B1 (cg-RX-API-DMAC7.html)
SI (1) SI3506921T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202300251T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018042415A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7232752B2 (ja) 2016-08-28 2023-03-03 マピ ファーマ リミテッド 酢酸グラチラマーを含有する微小粒子を調製する方法
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
EP4493274A1 (en) 2022-03-17 2025-01-22 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE55260T1 (de) 1985-10-11 1990-08-15 Duphar Int Res Automatische spritze.
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
NZ325561A (en) 1996-01-24 1999-06-29 Us Army Pharmaceutical composition containing an active ingredient and poly(lactide/glycolide) microcapsules which is a burst free controlled release formulation
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US20070185032A1 (en) 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU2868699A (en) 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP2239269B1 (en) 1998-09-25 2013-01-16 Yeda Research And Development Co., Ltd. Use of peptides derived from copolymer-1 as molecular weight markers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE60041365D1 (de) 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US6531130B1 (en) 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
DE60112718T2 (de) 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
MXPA02008023A (es) 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
EP1292279A4 (en) 2000-06-05 2005-01-12 Teva Pharma USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DE60116467T2 (de) 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US8658627B2 (en) 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
DE02800437T1 (de) 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
WO2003048207A2 (en) 2001-11-28 2003-06-12 Immunomedics, Inc. Anti-dota antibody
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
PL205469B1 (pl) 2001-12-06 2010-04-30 Yeda Res & Dev Zastosowanie Cop 1
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
DE10237146A1 (de) 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
EP1572271A1 (de) 2002-11-25 2005-09-14 Tecpharma Licensing AG Autoinjektor mit rückstellbarer auslösesicherung
CN1758922A (zh) 2003-01-07 2006-04-12 耶达研究及发展有限公司 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
RU2339397C2 (ru) 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
US20070037740A1 (en) 2003-03-04 2007-02-15 Irit Pinchasi Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
PT1638589E (pt) 2003-05-14 2014-06-12 Teva Pharma Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20060276390A1 (en) 2003-07-31 2006-12-07 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
NZ546379A (en) 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
NZ549731A (en) 2004-03-01 2009-11-27 Peptimmune Inc Methods and compositions for treatment of autoimmune diseases
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7576051B2 (en) 2004-03-11 2009-08-18 Sanyo Chemical Industries, Ltd. Wound dressing for accelerating epidermal regeneration
JP5162236B2 (ja) 2004-03-25 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2005120542A2 (en) 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
US8053197B2 (en) 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1796710A4 (en) 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
RS52265B (sr) 2004-09-09 2012-10-31 Teva Pharmaceutical Industries Ltd. Proces za dobijanje smeša trifluoracetil glatiramer acetata uz upotrebu prečišćene bromovodonične kiseline
ES2331015T3 (es) 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
EP1827491A4 (en) 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
AU2005308396B2 (en) 2004-11-29 2011-06-09 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
CA2594022A1 (en) 2005-02-02 2006-08-10 Teva Pharmaceutical Industries Ltd. Process for producing polypeptide mixtures using hydrogenolysis
CA2596842A1 (en) 2005-02-02 2006-08-10 Yeda Research & Development Co. Ltd Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
WO2006089066A1 (en) 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
US20060240463A1 (en) 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007021970A2 (en) 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US20070161566A1 (en) 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
WO2007100763A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
PT2002258T (pt) 2006-03-15 2017-12-18 The Brigham And Women`S Hospital Inc Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas
AU2007244643B2 (en) 2006-04-28 2013-05-02 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
WO2008001380A2 (en) 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration
TWI527603B (zh) 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
ATE452140T1 (de) 2006-07-05 2010-01-15 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
US20080248122A1 (en) 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
JP2010513283A (ja) 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
ES2599227T3 (es) 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
PL2187882T3 (pl) 2007-07-11 2013-05-31 Medicinova Inc Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
CN101808515A (zh) 2007-09-25 2010-08-18 雅培制药有限公司 作为趋化因子受体拮抗剂的八氢并环戊二烯化合物
WO2009042892A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009063459A2 (en) 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
WO2010011879A2 (en) 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
CN101827522A (zh) 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010045265A1 (en) 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
US20110268699A1 (en) 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
BRPI1008602A8 (pt) 2009-02-18 2018-01-02 Eyeon Particle Sciences Llc uso de co-polímero bi-funcional para as aplicações oftálmicas e outras aplicações tópicas e locais
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NZ577731A (en) 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
ES2383347T3 (es) 2009-07-15 2012-06-20 Teva Pharmaceutical Industries, Ltd. Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
AU2013203367C1 (en) 2009-08-20 2018-01-18 Yeda Research & Development Co., Ltd Low frequency glatiramer acetate therapy
WO2011048208A1 (en) 2009-10-22 2011-04-28 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with cns or pns demyelination
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011100567A1 (en) 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic inhibition of granulocyte function in demyelinating disease
PL2533634T3 (pl) 2010-02-12 2016-04-29 Biogen Ma Inc Neuroprotekcja w chorobach demielinizacyjnych
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013002230A2 (pt) 2010-07-29 2016-05-24 Reddys Lab Inc Dr marcadores de peso molecular de acetato de glatiramer
EP2605797A2 (en) 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
GB2485169A (en) 2010-11-03 2012-05-09 Univ Jw Goethe Frankfurt Main (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP2500072A1 (en) 2011-03-15 2012-09-19 LEK Pharmaceuticals d.d. A novel process of residual solvent removal
NZ616308A (en) 2011-04-08 2016-03-31 Biogen Ma Inc Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof
MX2013011978A (es) 2011-04-15 2015-06-10 Compugen Ltd Polipeptidos y polinucleotidos, y usos de los mismos para el tratamiento de transtornos inmunorelacionados y cancer.
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
US11340224B2 (en) 2011-05-04 2022-05-24 Cellular Technology Limited Whole brain lysate antigen-specific memory B cell and antibody assays in multiple sclerosis
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1206283A1 (en) 2012-03-12 2016-01-08 Medimmune, Llc Treatment of multiple sclerosis with anti-cd19 antibody
GB201208850D0 (en) 2012-05-18 2012-07-04 Alphaptose Gmbh Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
US9132138B2 (en) 2012-08-27 2015-09-15 Casi Pharmaceuticals, Inc. Method for the treatment of multiple sclerosis
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
BR112015016169A2 (pt) 2013-01-04 2017-07-11 Teva Pharma caracterizando produtos de drogas relacionados a acetato de glatirâmero
WO2014110154A1 (en) 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
CN105163737A (zh) 2013-02-15 2015-12-16 梯瓦制药工业有限公司 用拉喹莫德治疗多发性硬化症
JP2016512552A (ja) 2013-03-12 2016-04-28 テバ ファーマシューティカル インダストリーズ リミティド リツキシマブ導入療法とその後の酢酸グラチラマー療法
US20160040236A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
CN103169670B (zh) 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
AU2014319921A1 (en) 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
EP3189026B1 (en) 2014-09-02 2020-07-22 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
WO2016040861A1 (en) 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
WO2016064997A1 (en) 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US20160213633A1 (en) 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response
WO2016160830A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of providing neuroprotective therapy
EP3277285B1 (en) 2015-03-30 2024-07-17 The Regents of the University of California Estriol for reducing cortical gray matter atrophy
JP7232752B2 (ja) 2016-08-28 2023-03-03 マピ ファーマ リミテッド 酢酸グラチラマーを含有する微小粒子を調製する方法
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
CA3062964C (en) 2017-05-15 2024-11-12 Mapi Pharma Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: 8 August 2014 (2014-08-08), XP055679718, Retrieved from the Internet [retrieved on 20200325] *

Also Published As

Publication number Publication date
IL301455A (en) 2023-05-01
SMT202300251T1 (it) 2023-09-06
CA3035147A1 (en) 2018-03-08
MX2019002284A (es) 2019-09-04
ES3023741T3 (en) 2025-06-03
FI3506921T3 (fi) 2023-07-21
LT3506921T (lt) 2023-08-10
IL264914A (cg-RX-API-DMAC7.html) 2019-04-30
PT3506921T (pt) 2023-08-07
PL3506921T3 (pl) 2023-08-21
HRP20250396T1 (hr) 2025-05-23
IL264914B2 (en) 2023-08-01
PL4252849T3 (pl) 2025-04-28
WO2018042415A1 (en) 2018-03-08
CN109982712A (zh) 2019-07-05
EP4252849B1 (en) 2025-02-19
EP3506921B1 (en) 2023-05-17
EP3506921A1 (en) 2019-07-10
IL301455B1 (en) 2023-12-01
SI3506921T1 (sl) 2023-10-30
ES2952044T3 (es) 2023-10-26
EP3506921A4 (en) 2020-05-06
JP2019530648A (ja) 2019-10-24
EP4252849C0 (en) 2025-02-19
HUE071047T2 (hu) 2025-07-28
HRP20230738T1 (hr) 2023-10-27
DK3506921T3 (da) 2023-07-31
EP4252849A3 (en) 2023-11-01
RS66690B1 (sr) 2025-05-30
RS64445B1 (sr) 2023-09-29
US20210283209A1 (en) 2021-09-16
BR112019003594A2 (pt) 2019-05-21
IL301455B2 (en) 2024-04-01
HUE062393T2 (hu) 2023-11-28
US12370233B2 (en) 2025-07-29
IL264914B1 (en) 2023-04-01
EP4252849A2 (en) 2023-10-04
AU2017319728A1 (en) 2019-02-07
JP7193448B2 (ja) 2022-12-20
SMT202500136T1 (it) 2025-05-12

Similar Documents

Publication Publication Date Title
AU2017319728B2 (en) Depot systems comprising glatiramer acetate
US12343371B2 (en) Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP2016074696A (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE50301E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HK40005874A (en) Depot systems comprising glatiramer acetate
HK40010052A (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)